The landscape in the pharmaceutical world is forever changing, as drug costs continue to rise and drug plan sustainability is at risk, said Alberta Blue Cross’ Krystal Wynnyk at the 2018 Calgary Drug Trends Summit on Oct. 25. “We’re stuck trying to find a balance between plan sponsor costs and drug sustainability, and balancing that […]
Private drug plans are hugely valuable, for employees and employers alike, and they need to continue to be a part of the national drug landscape, even with a pharmacare program, said one speaker at the 2018 Calgary Drug Trends Summit. At the same time, drug costs are creating sustainability issues, said Sarah Lussier Hoskyn, senior analyst of […]
Many effective strategies exist when it comes to managing specialty drug costs, but a coordinated approach that takes the financial, clinical and pharmacy elements into account is key to achieving a balance between access and spending, according to Telus Health’s Cory Cowan. Cowan, the organization’s director of professional services, told attendees at the 2018 Pharmacy […]
On Sept. 20, the 2018 Halifax Benefits Summit featured insightful sessions on benefits, health and wellness and drug plan trends. With population numbers struggling in the Maritimes, the conference looked at how companies can ensure they’re providing plan members with the best, most competitive benefits options in order to attract and retain talent. Here are some of the highlights of […]
While the impact of biologics on patients has proven successful, it’s counterbalanced by an equally significant fiscal impact, delegates heard at the 2018 Halifax Benefits Summit in September. “The impact of biologics on patients is incredible,” said Ned Pojskic, leader of pharmacy and health provider relations at Green Shield Canada. However, he added, the industry has to […]
Don’t confuse biosimilars with generic drugs, cautioned Dr. Ian Blumer at the 2018 Halifax Benefits Summit in September. While the terms may be used interchangeably, these two types of drugs aren’t the same thing, said the endocrinologist and director of the Charles H. Best Diabetes Centre in Whitby, Ont., during his presentation. “Generic drugs are chemicals. […]
A positive attitude is the key to a long and fulfilling life with chronic disease, according to a man who has spent almost four decades dealing with rheumatoid arthritis. “The mental approach you take to anything in life and the perspective you have is absolutely critical,” said Jeff Aarssen, who provided a patient’s perspective during […]
A recent study examining the potential savings determined that, based on the uptake of available biosimilars in Organisation for Economic Co-operation and Development countries, Canada could save between eight per cent and 43 per cent. Although Health Canada approved Inflectra, the first biosimilar for Remicade, in 2014 to treat a number of conditions, the drug […]
Canada could save an estimated $280 million a year in drug costs if biosimilar uptake here reached the levels seen in Norway, a speaker told attendees at a recent event in Calgary. “One problem with biosimilars is their uptake,” Andrea Staruch, a pharmacy services consultant at Green Shield Canada, said during a presentation at Benefits […]
From drug pooling to medical marijuana, plan sponsors have a number of issues to keep track of when it comes to their benefits plans. At the Face to Face Drug Plan Management forum in Vancouver this month, a panel of experts tackled some of the hot topics the industry is thinking about. Pooling: One concern […]